导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.93% | 3386/4773 |
| 近一周 | 0.61% | 198/5458 |
| 近一月 | 4.68% | 130/5421 |
| 近一季 | 2.98% | 440/5205 |
| 近半年 | 2.02% | 1040/4920 |
| 近一年 | -1.76% | 2983/4361 |
| 近两年 | 34.68% | 2139/2954 |
| 近三年 | 34.70% | 885/2253 |
| 成立以来 | 126.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.06% 4339/4961 |
-4.91% 3533/5312 |
- - |
- - |
| 2025 | 13.15% 2659/4813 |
0.07% 1988/3635 |
9.54% 277/4076 |
-4.15% 4022/4524 |
7.68% 285/4813 |
| 2024 | 35.90% 51/3463 |
4.61% 443/2808 |
2.98% 293/3014 |
23.42% 400/3129 |
2.22% 974/3463 |
| 2023 | -0.79% 475/2656 |
-1.31% 1861/2280 |
2.85% 121/2385 |
5.35% 90/2515 |
-7.23% 2092/2655 |
| 2022 | -9.04% 165/2207 |
-4.63% 170/1919 |
-1.12% 1676/2016 |
-9.77% 308/2113 |
6.90% 339/2208 |
| 2021 | -9.82% 1085/1822 |
-0.75% 392/1255 |
-3.54% 1248/1330 |
-5.78% 858/1466 |
-0.03% 1185/1822 |
| 2020 | 2.13% 925/1250 |
-13.98% 945/1028 |
3.70% 931/1067 |
9.05% 679/1164 |
4.98% 820/1184 |
| 2019 | 31.42% 469/1092 |
24.55% 503/754 |
1.73% 113/804 |
-2.54% 704/850 |
6.43% 610/918 |
| 2018 | -15.91% 103/834 |
- - |
- - |
- - |
-9.95% 170/691 |
| 2017 | 20.92% 173/714 |
- - |
- - |
- - |
- - |
| 2016 | -4.06% 155/605 |
- - |
- - |
- - |
- - |
| 2015 | -9.04% 291/575 |
- - |
- - |
- - |
- - |
| 2014 | 79.59% 9/237 |
- - |
- - |
- - |
- - |
| 2013 | -6.39% 114/186 |
- - |
- - |
- - |
- - |
| 2012 | 19.14% 4/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国泰上证180金融ETF联接A VS. 长安沪深300非周期A(740101) |